

CLAIMS

We Claim:


~~1. An ASGPR-binding extracellular protein degrader compound of formula:~~




~~(I),~~




~~(I-d),~~




~~(II),~~




~~(II-d),~~




~~(III),~~




~~(III-d),~~




~~(IV),~~




~~(IV-d),~~




~~(V),~~




~~(V-d),~~




~~(VI),~~




~~(VI-d),~~




~~(VII),~~




~~(VIII),~~




~~(I-Bi),~~




~~(I-d-Bi),~~




~~(II-Bi),~~




~~(II-d-Bi),~~




~~(III-Bi),~~




~~(III-d-Bi),~~




~~(IV-Bi),~~




~~(IV-d-Bi),~~




~~(V-Bi),~~




~~(V-d-Bi),~~




~~(VI-Bi),~~




~~(VI-d-Bi),~~




~~(VII-Bi),~~


R5
O
Linker^A
Cycle
HO
OH
Linker^A
Linker^C
Extracellular Protein Targeting Ligand
R5
O
Cycle
HO
OH


~~(VIII-Bi),~~


Linker^A
O
O
HO
R2
OH
Extracellular Protein Targeting Ligand
Linker^D
Linker^A
O
O
HO
R2
OH
Linker^A
O
O
HO
R2
OH


~~(I-Tri),~~


Linker^A
Extracellular Protein Targeting Ligand
Linker^D
Linker^A
Linker^A
HO
R2
OH
O


~~(I-d-Tri),~~


Linker^A
Linker^A
Linker^D
Extracellular Protein Targeting Ligand
Linker^A
HO
R2
OH
O


- ~~(II-Tri),~~




~~(II-d-Tri),~~




~~(III-Tri),~~




~~(III-d-Tri),~~




~~(IV-Tri),~~


X1
O
Linker^A
HO
R2
OH
X1
O
Linker^A
Linker^D
Extracellular Protein Targeting Ligand
HO
R2
OH
X1
O
Linker^A
HO
R2
OH


~~(IV-d-Tri),~~


Linker^A
O
R1
HO
R2
OH
Extracellular Protein Targeting Ligand
Linker^D
Linker^A
O
R1
HO
R2
OH
Linker^A
O
R1
HO
R2
OH


~~(V-Tri),~~


Linker^A
O
R^1
HO
R^2
OH
Extracellular Protein Targeting Ligand
Linker^D
Linker^A
O
R^1
HO
R^2
OH
Linker^A
O
R^1
HO
R^2
OH


~~(V-d-Tri),~~


R^5
O
Linker^A
HO
R^2
OH
R^5
O
Linker^A
Linker^D
Extracellular Protein Targeting Ligand
HO
R^2
OH
R^5
O
Linker^A
HO
R^2
OH


- ~~(VI-Tri),~~



~~(VI-d-Tri),~~



~~(VII-Tri), or~~



~~(VIII-Tri),~~


~~or a pharmaceutically acceptable salt thereof~~

~~wherein:~~

~~X^1 is 1 to 5 groups independently selected from O, S, N(R^6), and C(R^4)(R^4), wherein if X^1 is 1 group then X^1 is O, S, N(R^6), or C(R^4)(R^4), if X^1 is 2 groups then no more than 1 group of X^1 is O, S, or N(R^6), if X^1 is 3, 4, or 5 groups then no more than 2 groups of X^1 are O, S, or N(R^6);~~

~~R^2 is selected from~~

~~(i) aryl, heterocycle, and heteroaryl containing 1 or 2 heteroatoms independently selected from N, O, and S, each of which aryl, heterocycle, and heteroaryl is optionally substituted with 1, 2, 3, or 4 substituents;~~

~~(ii)~~  ~~, and~~ ~~;~~

~~(iii) $-NR^8-S(O)-R^3$, $-NR^8-C(S)-R^3$, $-NR^8-S(O)(NR^6)-R^3$, $-N=S(O)(R^3)_2$, $-NR^8C(O)NR^9S(O)_2R^3$, $NR^8-S(O)_2-R^{10}$, and $NR^8-C(NR^6)-R^3$ each of which is optionally substituted with 1, 2, 3, or 4 substituents; and~~

(iv) hydrogen, R^{10}, alkyl-C(O)-R^3, -C(O)-R^3, alkyl, haloalkyl, -OC(O)R^3, and -NR^8-C(O)R^{10};

R^{10} is selected from aryl, alkyl-NR^8-C(O)-R^3, alkyl-aryl, alkyl-heteroaryl with 1, 2, or 4 heteroatoms, alkyl-cyano, alkyl-OR^6, alkyl-NR^6R^8, NR^8-NR^6-C(O)R^3, NR^8-$S(O)_2$-R^3, alkenyl, allyl, alkynyl, -NR^6-alkenyl, -O-alkenyl, -NR^6-alkynyl, -NR^6-heteroaryl, -NR^6-aryl, -O-heteroaryl, -O-aryl, and -O-alkynyl, each of which R^{10} is optionally substituted with 1, 2, 3, or 4 substituents;

R^1 and R^5 are independently selected from hydrogen, heteroalkyl, C_0-C_6alkyl-cyano, alkyl, alkenyl, alkynyl, haloalkyl, F, Cl, Br, I, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocycloalkyl, haloalkoxy, -O-alkenyl, -O-alkynyl, C_0-C_6alkyl-OR^6, C_0-C_6alkyl-SR^6, C_0-C_6alkyl-NR^6R^7, C_0-C_6alkyl-C(O)R^3, C_0-C_6alkyl-S(O)R^3, C_0-C_6alkyl-C(S)R^3, C_0-C_6alkyl-$S(O)_2R^3$, C_0-C_6alkyl-$N(R^8)$-C(O)R^3, C_0-C_6alkyl-$N(R^8)$-S(O)R^3, C_0-C_6alkyl-$N(R^8)$-C(S)R^3, C_0-C_6alkyl-$N(R^8)$-$S(O)_2R^3$, C_0-C_6alkyl-O-C(O)R^3, C_0-C_6alkyl-O-S(O)R^3, C_0-C_6alkyl-O-C(S)R^3, -N=S(O)$(R^3)_2$, C_0-C_6alkylN_3, and C_0-C_6alkyl-O-$S(O)_2R^3$, each of which is optionally substituted with 1, 2, 3, or 4 substituents;

R^3 at each occurrence is independently selected from hydrogen, alkyl, heteroalkyl, haloalkyl (including $-CF_3$, $-CHF_2$, $-CH_2F$, $-CH_2CF_3$, $-CH_2CH_2F$, and $-CF_2CF_3$), arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, $-OR^8$, and $-NR^8R^9$;

R^4 is independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, haloalkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, $-OR^6$, $-NR^6R^7$, C(O)R^3, S(O)R^3, C(S)R^3, and $S(O)_2R^3$;

R^6 and R^7 are independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, haloalkyl, heteroaryl, heterocycle, -alkyl-OR^8, -alkyl-NR^8R^9, C(O)R^3, S(O)R^3, C(S)R^3, and $S(O)_2R^3$;

R^8 and R^9 are independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocycle;

Cycle is a 3-8 membered fused cyclic group optionally substituted with 1, 2, 3, or 4 substituents;



each $Linker^A$ is a bond or a moiety that covalently links the ASGPR ligand to $Linker^B$;

$Linker^B$ is a bond or a moiety that covalently links $Linker^A$ to an Extracellular Protein Targeting Ligand;


~~Linker^{C} is a chemical group that links each Linker^{A} to the Extracellular Protein Targeting Ligand; and~~

~~Linker^{D} is a chemical group that links each Linker^{A} to the Extracellular Protein Targeting Ligand; and~~


~~wherein, when R^2 is NR^6-alkenyl, $-NR^6$-alkynyl, NR^8-$C(O)R^{10}$, $-NR^8$-$S(O)_2$-alkenyl, $-NR^8$-$S(O)_2$-alkynyl, $-NR^6$-heteroaryl, or $-NR^6$-aryl, then Extracellular Protein Targeting Ligand does not comprise an oligonucleotide; and~~

~~the optional substituents are selected from alkyl, alkenyl, alkynyl, haloalkyl, $-OR^6$, F, Cl, Br, I, NR^6R^7, heteroalkyl, cyano, nitro, $C(O)R^3$,~~  ~~, and~~  ~~, as allowed by valence such that a stable compound results.~~


2. ~~The compound of claim 1, wherein R^{10} is selected from alkenyl, allyl, alkynyl, $-NR^6$-alkenyl, $-O$-alkenyl, $-NR^6$-alkynyl, $-O$-alkynyl, $-NR^6$-heteroaryl, $-NR^6$-aryl, $-O$-heteroaryl, $-O$-aryl, and $-O$-alkynyl, each of which R^{10} is optionally substituted with 1, 2, 3, or 4 substituents.~~
3. ~~The compound of claim 1 or 2, wherein R^2 is aryl optionally substituted with 1, 2, or 3 substituents.~~
4. ~~The compound of claim 1 or 2, wherein R^2 is heterocycle optionally substituted with 1, 2, or 3 substituents.~~
5. ~~The compound of claim 1 or 2, wherein R^2 is heteroaryl containing 1 or 2 heteroatoms independently selected from N, O, and S optionally substituted with 1, 2, or 3 substituents.~~
6. ~~The compound of claim 1 or 2, wherein R^2 is selected from:~~

 ~~, and~~ .


7. ~~The compound of claim 1 or 2, wherein R^2 is selected from:~~


 ~~, and~~ .

8. The compound of claim 1 or 2, wherein R^2 is selected from:




9. The compound of claim 1 or 2, wherein R^2 is selected from:







10. The compound of claim 1 or 2, wherein R^2 is selected from:




11. The compound of claim 1 or 2, wherein R^2 is selected from:






12. The compound of claim 1 or 2, wherein R^2 is selected from:




13. The compound of claim 1 or 2, wherein R^2 is selected from:




14. The compound of claim 1 or 2, wherein R^2 is selected from alkenyl, alkynyl, $-NR^6$-alkenyl, -O-alkenyl, $-NR^6$-alkynyl, -O-alkynyl, alkyl-C(O)alkyl, alkyl, haloalkyl, $-OC(O)R^3$, and $-NR^6-C(O)R^{10}$.

15. The compound of any one of claims 1 to 14, wherein the compound is of Formula



or a pharmaceutically acceptable salt thereof.


16. The compound of any one of claims 1 to 14, wherein the compound is of Formula



;

or a pharmaceutically acceptable salt thereof.


17. The compound of any one of claims 1 to 14, wherein the compound is of Formula



;

or a pharmaceutically acceptable salt thereof.

18. The compound of any one of claims 1 to 14, wherein the compound is of Formula



;


or a pharmaceutically acceptable salt thereof.

19. The compound of claim 17 or 18, wherein X_1 is 2, 3, or 4 groups selected from O, S, $N(R^6)$, and $C(R^4)(R^4)$.

20. The compound of claim 17 or 18, wherein X_1 is $-O-C(R^4)(R^4)-$, $-C(R^4)(R^4)-NR^6-$, or $-C(R^4)(R^4)-S-$.

21. The compound of claim 20, wherein each R^4 is hydrogen.


22. The compound of any one of claims 1 to 14, wherein the compound is of Formula



;

~~or a pharmaceutically acceptable salt thereof.~~


~~23. The compound of any one of claims 1 to 14, wherein the compound is of Formula~~




;

~~or a pharmaceutically acceptable salt thereof.~~

~~24. The compound of any one of claims 1 to 14, wherein the compound is of Formula~~




~~or~~



;


~~or a pharmaceutically acceptable salt thereof.~~

~~25. The compound of claim 24, wherein Cycle is selected from:~~




.

~~26. The compound of claim 24, wherein Cycle is selected from:~~



~~27. The compound of claim 24, wherein Cycle is selected from:~~



~~28. The compound of any one of claims 1 to 27, wherein R^1 and R^5 are selected from hydrogen, alkyl, F, Cl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocycloalkyl, haloalkoxy, C_0-C_6alkyl-OR^6, C_0-C_6alkyl-SR^6, C_0-C_6alkyl-NR^6R^7, C_0-C_6alkyl-$C(O)R^3$, C_0-C_6alkyl-$S(O)R^3$, C_0-C_6alkyl-$C(S)R^3$, and C_0-C_6alkyl-$S(O)_2R^3$ each of which is optionally substituted with 1, 2, 3, or 4 substituents.~~

~~29. The compound of any one of claims 1 to 27, wherein R^1 and R^5 are selected from hydrogen, C_0-C_6alkyl-OR^6, C_0-C_6alkyl-SR^6, C_0-C_6alkyl-NR^6R^7, C_0-C_6alkyl-$C(O)R^3$, C_0-C_6alkyl-$S(O)R^3$, C_0-C_6alkyl-$C(S)R^3$, and C_0-C_6alkyl-$S(O)_2R^3$ each of which is optionally substituted with 1, 2, or 3 substituents.~~

~~30. The compound of any one of claims 1 to 27, wherein R^1 and R^5 are selected from hydrogen, C_0-C_6alkyl-OR^6, and C_0-C_6alkyl-NR^6R^7.~~

~~31. The compound of any one of claims 1 to 30, wherein R^3 is selected from aryl, heteroaryl, and heterocycle.~~

~~32. The compound of any one of claims 1 to 30, wherein R^3 is $-OR^8$.~~

~~33. The compound of any one of claims 1 to 30, wherein R^3 is $-NR^8R^9$.~~

34. The compound of any one of claims 1 to 33, wherein R^6 and R^7 are independently selected at each occurrence from hydrogen, alkyl, aryl, haloalkyl, heteroaryl, heterocycle, $C(O)R^3$, $S(O)R^3$, $C(S)R^3$, and $S(O)_2R^3$.

35. The compound of any one of claims 1 to 33, wherein R^6 and R^7 are independently selected at each occurrence from hydrogen, alkyl, and $C(O)R^3$, $S(O)R^3$, $C(S)R^3$, and $S(O)_2R^3$.


36. The compound of any one of claims 1 to 35, wherein at least one of R^6 and R^7 are hydrogen.

37. The compound of any one of claims 1 to 36, wherein R^8 and R^9 are independently selected at each occurrence from hydrogen, alkyl, aryl, heteroaryl, and heterocycle.


38. The compound of any one of claims 1 to 36, wherein R^8 and R^9 are independently selected at each occurrence from hydrogen and alkyl.


39. The compound of any one of claims 1 to 36, wherein R^8 and R^9 are both hydrogen at each occurrence.

40. The compound of any one of claims 1 to 39, wherein $Linker^A$ is selected from:



, , and .

41. The compound of any one of claims 1 to 39, wherein $Linker^A$ is selected from:



, , , and


.

42. The compound of any one of claims 1 to 39, wherein $Linker^A$ is selected from:


, , and .

43. The compound of any one of claims 1 to 42, wherein $Linker^B$ is:


;

wherein:

R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, and R^{20} are independently at each occurrence selected from the group consisting of a bond, alkyl, -C(O)-, -C(O)O-, -OC(O)-, $-SO_2-$, -S(O)-, -C(S)-, -C(O)NR^6-, $-NR^6C(O)-$, -O-, -S-, $-NR^6-$, $-C(R^{21}R^{21})-$, $-P(O)(R^3)O-$, $-P(O)(R^3)-$, a divalent residue of a natural or unnatural amino acid, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, heterocycle, heteroaryl, $-CH_2CH_2-[O-(CH_2)_2]_n-O-$, $-CH_2CH_2-[O-(CH_2)_2]_n-NR^6-$, $-CH_2CH_2-[O-(CH_2)_2]_n-$, $-[(CH_2)_2-O]_n-$, $-[O-(CH_2)_2]_n-$, $-[O-CH(CH_3)C(O)]_n-$, $-[C(O)-CH(CH_3)-O]_n-$, $-[O-CH_2C(O)]_n-$, $-[C(O)-CH_2-O]_n-$, a divalent residue of a fatty acid, a divalent residue of an unsaturated or saturated mono- or di-carboxylic acid, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^{21};

n is independently selected at each instance from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and



R^{21} is independently at each occurrence selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, F, Cl, Br, I, hydroxyl, alkoxy, azide, amino, cyano, $-NR^6R^7$, $-NR^8SO_2R^3$, $-NR^8S(O)R^3$, haloalkyl, heteroalkyl, aryl, heteroaryl, heterocyclyl, $-SR^3$, $-C(O)OR^3$, $-C(O)NR^6NR^7$, $-OR^3$,  and heterocycle.

44. The compound of claim 43, wherein R^{21} is independently at each occurrence selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, F, Cl, Br, I, hydroxyl, alkoxy, azide, amino, cyano, $-NR^6R^7$, $-NR^8SO_2R^3$, $-NR^8S(O)R^3$, haloalkyl, heteroalkyl, aryl, heteroaryl, and heterocycle.





45. The compound of claim 43 or 44, wherein 1, 2, 3, or 4 of R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, and R^{19} is bond.

46. The compound of claim 43 or 44, wherein 1, 2, 3, or 4 of R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, and R^{19} is an amino acid.


47. The compound of any one of claims 1 to 46, wherein $Linker^B$ is selected from:

, , and .


~~48. The compound of any one of claims 1 to 46, wherein Linker^B is selected from:~~


~~49. The compound of any one of claims 1 to 42, wherein the compound is selected from:~~




~~(I-Bi),~~




~~(II-Bi),~~




~~(III-Bi),~~




~~(IV-Bi),~~




~~(V-Bi),~~



~~(VI-Bi),~~




~~(VII-Bi), and~~



~~(VIII-Bi);~~

~~or a pharmaceutically acceptable salt thereof.~~

~~50. The compound of claim 49, wherein Linker^C is selected from:~~



wherein:

R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, and R^{20} are independently at each occurrence selected from the group consisting of a bond, alkyl, -C(O)-, -C(O)O-, -OC(O)-, $-SO_2$-, -S(O)-, -C(S)-, -C(O)NR^6-, -NR^6C(O)-, -O-, -S-, -NR^6-, -C($R^{21}R^{21}$)-, -P(O)(R^3)O-, -P(O)(R^3)-, a divalent residue of a natural or unnatural amino acid, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, heterocycle, heteroaryl, $-CH_2CH_2-[O-(CH_2)_2]_n-O-$, $-CH_2CH_2-[O-(CH_2)_2]_n-NR^6-$, $-CH_2CH_2-[O-(CH_2)_2]_n-$, $-[(CH_2)_2-O]_n-$, $-[O-(CH_2)_2]_n-$, $-[O-CH(CH_3)C(O)]_n-$, $-[C(O)-CH(CH_3)-O]_n-$, $-[O-CH_2C(O)]_n-$, $-[C(O)-CH_2-O]_n-$, a divalent residue of a fatty acid, a divalent residue of an unsaturated or saturated mono- or di-carboxylic acid, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^{21};


n is independently selected at each instance from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

R^{21} is independently at each occurrence selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, F, Cl, Br, I, hydroxyl, alkoxy, azide, amino, cyano, -NR^6R^7, -$NR^8SO_2R^3$, -$NR^8S(O)R^3$, haloalkyl, heteroalkyl, aryl, heteroaryl, heterocyclyl, -SR^3, -C(O)OR^3, -C(O)NR^6NR^7, -OR^3,  and heterocycle; and

R^{22} is independently at each occurrence selected from the group consisting of alkyl, -C(O)N-, -NC(O)-, -N-, -C(R^{21})-, -P(O)O-, -P(O)-, -P(O)(NR^6R^7)N-, alkenyl, haloalkyl, aryl, heterocycle, and heteroaryl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^{21}.


51. The compound of claim 50, wherein R^{21} is independently at each occurrence selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, F, Cl, Br, I, hydroxyl, alkoxy, azide, amino, cyano, NR^6R^7, -$NR^8SO_2R^3$, -$NR^8S(O)R^3$, haloalkyl, heteroalkyl, aryl, heteroaryl, and heterocycle.

~~52. The compound of claim 50 or 51, wherein Linker^C is selected from:~~




~~, and~~


~~53. The compound of any one of claims 1 to 42, wherein the compound is selected from:~~




~~(I-Tri),~~




- ~~(II-Tri),~~




~~(III-Tri),~~


X1
O
Linker^A
HO
R2
OH
X1
O
Linker^A
Linker^D
Extracellular Protein Targeting Ligand
HO
R2
OH
X1
O
Linker^A
HO
R2
OH


~~(IV-Tri),~~


Linker^A
O
R1
HO
R2
OH
Extracellular Protein Targeting Ligand
Linker^D
Linker^A
O
R1
HO
R2
OH
Linker^A
O
R1
HO
R2
OH


~~(V-Tri),~~



- ~~(VI-Tri),~~




~~(VII-Tri), and~~



~~(VIII-Tri);~~

~~or a pharmaceutically acceptable salt thereof.~~

~~54. The compound of claim 53, wherein Linker^D is selected from:~~



~~;~~

~~wherein:~~


~~R^{32} is independently at each occurrence selected from the group consisting of alkyl, N^+X^-, =C-, alkenyl, haloalkyl, aryl, heterocycle, and heteroaryl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^{21}; and~~

~~X^- is an anionic group.~~

~~55. The compound of any one of claims 1 to 54, wherein the Extracellular Protein Targeting Ligand targets an immunoglobin.~~

~~56. The compound of any one of claims 1 to 55, wherein the Extracellular Protein Targeting Ligand targets IgA.~~

~~57. The compound of claim 56, wherein the Extracellular Protein Targeting Ligand is:~~



~~58. The compound of any one of claims 1 to 55, wherein the Extracellular Protein Targeting Ligand targets IgG.~~

~~59. The compound of any one of claims 1 to 55, wherein the Extracellular Protein Targeting Ligand targets IgE.~~

~~60. The compound of any one of claims 1 to 54, wherein the Extracellular Protein Targeting Ligand targets TNF-α.~~

~~61. The compound of any one of claims 1 to 54, wherein the Extracellular Protein Targeting Ligand targets IL-1b.~~

~~62. The compound of any one of claims 1 to 54, wherein the Extracellular Protein Targeting Ligand targets IL-2.~~

~~63. The compound of any one of claims 1 to 54, wherein the Extracellular Protein Targeting Ligand targets IL-6.~~

~~64. The compound of any one of claims 1 to 54, wherein the Extracellular Protein Targeting Ligand targets IFN-γ.~~

65. The compound of any one of claims 1 to 54, wherein the Extracellular Protein Targeting Ligand targets VEGF.

66. The compound of any one of claims 1 to 54, wherein the Extracellular Protein Targeting Ligand targets TGF-b1.

67. The compound of any one of claims 1 to 54, wherein the Extracellular Protein Targeting Ligand targets PCSK-9.

68. A pharmaceutical composition comprising a compound of any one of claims 1 to 67 and a pharmaceutically acceptable carrier.

69. A method of treating a disorder mediated by an effective amount of Extracellular Protein comprising administering a compound of any one of claims 1 to 67 that includes an Extracellular Protein Targeting Ligand that binds to the Extracellular Protein, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

70. The method of claim 69, wherein the extracellular protein is IgA and the disorder is selected from IgA nephropathy (Berger's disease), celiac disease, Crohn's disease, Henoch-Sconiein purpura (HSP), liner IgA bullous dermatosis, IgA pemphigus, dermatitis herpetiformis, inflammatory bowel disease (IBD), Sjögren's syndrome, ankylosing spondylitis, alcoholic liver cirrhosis, acquired immunodeficiency syndrome, IgA multiple myeloma, α chain disease, IgA monoclonal gammopathy, monoclonal gammopathy of undetermined significance (MGUS), and linear IgA bullous dermatosis.

71. The method of claim 69, wherein the extracellular protein is IgG and the disorder is selected from type 1 autoimmune pancreatitis, interstitial nephritis, Riedel's thyroiditis, storiform fibrosis, Mikulicz's disease, Küttner's tumor, inflammatory pseudotumors, mediastinal fibrosis, retroperitoneal fibrosis (Ormond's disease), aortitis, periaortitis, proximal biliary strictures, idiopathic hypocomplementic tubulointerstitial nephritis, multifocal fibrosclerosis, pachymeningitis, pancreatic enlargement, tumefactive lesions, pericarditis, rheumatoid arthritis (RA), inflammatory bowel disease, multiple sclerosis, myasthenic gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, warm autoimmune hemolytic anemia, ankylosing spondylitis, primary Sjögren's syndrome, psoriatic arthritis, and systemic lupus erythematosus (SLE), sclerosing cholangitis, and IgG monoclonal gammopathy, monoclonal gammopathy of undetermined significance (MGUS).

72. The method of claim 69, wherein the extracellular protein is IgE and the disorder is selected from atopic asthma, allergic rhinitis, atopic dermatitis, IgE mediated food allergy, IgE-mediated animal allergies, allergic conjunctivitis, allergic urticaria, anaphylactic shock, nasal polyposis, keratoconjunctivitis, mastocytosis, and eosinophilic gastrointestinal disease, bullous pemphigoid, chemotherapy induced hypersensitivity reaction, seasonal allergic rhinitis, interstitial cystitis, eosinophilic esophagitis, angioedema, acute interstitial nephritis, atopic eczema, eosinophilic bronchitis, chronic obstructive pulmonary disease, gastroenteritis, hyper IgE syndrome (Job's Syndrome), IgE monoclonal gammopathy, and monoclonal gammopathy of undetermined significance (MGUS).

73. The method of claim 69, wherein the disorder is dementia or Alzheimer's disease.

74. The method of claim 69, wherein the extracellular protein is TNF α and the disorder is selected from rheumatoid arthritis, inflammatory bowel disease, graft vs host disease, ankylosing spondylitis, psoriasis, hidradenitis suppurativa, refractory asthma, systemic lupis erthyematosus, diabetes, and the induction of cachexia.


75. The method of claim 69, wherein the extracellular protein is IL-2 and the disorder is selected from host versus graft rejection in transplants and autoimmune disorders, including, but not limited to, multiple sclerosis, idiopathic arthritis, iritis, anterior uveitis, IL-2 induced hypotension, and psoriasis.

76. The method of claim 69, wherein the extracellular protein is IL-6 and the disorder is selected from Castleman's disease, metastatic castration-associated prostate cancer, renal cell carcinoma, large cell lung carcinoma, ovarian cancer, rheumatoid arthritis, and asthma.


77. The method of claim 69, wherein the extracellular protein is IFN γ and the disorder is selected from rheumatoid arthritis, multiple sclerosis (MS), corneal transplant rejection, and various autoimmune skin diseases such as psoriasis, alopecia areata, vitiligo, and acne vulgaris.

78. The method of claim 69, wherein the disorder is a cancer.


~~79. A compound of formula:~~




~~(IX),~~




~~(X),~~




~~(XI),~~




~~(XII),~~




~~(XIII),~~



~~(XIV),~~



~~(XV), or~~



~~(XVI),~~

~~or a salt thereof;~~

~~wherein:~~










~~R^L is selected from R^5 and Linker^E;~~

~~R^{L2} is selected from R^6 and Linker^E;~~

~~X^1 is 1 to 5 contiguous atoms independently selected from O, S, N(R^6), and C(R^4)(R^4), wherein if X^1 is 1 atom then X^1 is O, S, N(R^6), or C(R^4)(R^4), if X^1 is 2 atoms then no more than 1 atom of X^1 is O, S, or N(R^6), if X^1 is 3, 4, or 5 atoms then no more than 2 atoms of X^1 are O, S, or N(R^6);~~

~~R^{2A} is selected from~~

~~(i) aryl, heterocycle, and heteroaryl containing 1 or 2 heteroatoms independently selected from N, O, and S, each of which aryl, heterocycle, and heteroaryl is optionally substituted with 1, 2, 3, or 4 substituents;~~

(ii)  ,  ,  ,  ,  ;  ;  ;   ; and ; and

(iii) -NH-S(O)-R^3, -NR^8-C(S)-R^3, -NH-S(O)(NR^6)-R^3, and -N=S(O)(R^3)-NR^6R^7 each of which is optionally substituted with 1, 2, 3, or 4 substituents;

R^1 and R^5 are independently selected from hydrogen, heteroalkyl, C_0-C_6alkyl-cyano, alkyl, alkenyl, alkynyl, haloalkyl, F, Cl, Br, I, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocycloalkyl, haloalkoxy, -O-alkenyl, -O-alkynyl, C_0-C_6alkyl-OR^6, C_0-C_6alkyl-SR^6, C_0-C_6alkyl-NR^6R^7, C_0-C_6alkyl-C(O)R^3, C_0-C_6alkyl-S(O)R^3, C_0-C_6alkyl-C(S)R^3, C_0-C_6alkyl-$S(O)_2R^3$, C_0-C_6alkyl-$N(R^8)$-C(O)R^3, C_0-C_6alkyl-$N(R^8)$-S(O)R^3, C_0-C_6alkyl-$N(R^8)$-C(S)R^3, C_0-C_6alkyl-$N(R^8)$-$S(O)_2R^3$, C_0-C_6alkyl-O-C(O)R^3, C_0-C_6alkyl-O-S(O)R^3, C_0-C_6alkyl-O-C(S)R^3, N=S(O)(R^3)$_2$, C_0-C_6alkylN_3, and C_0-C_6alkyl-O-$S(O)_2R^3$, each of which is optionally substituted with 1, 2, 3, or 4 substituents;


R^3 at each occurrence is independently selected from hydrogen, alkyl, heteroalkyl, haloalkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, -OR^8, or -NR^8R^9;


R^4 is independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, haloalkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, -OR^6, -NR^6R^7, C(O)R^3, S(O)R^3, C(S)R^3, and $S(O)_2R^3$;

R^6 and R^7 are independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, haloalkyl, heteroaryl, heterocycle, alkyl-OR^8, -alkyl-NR^8R^9, C(O)R^3, S(O)R^3, C(S)R^3, and $S(O)_2R^3$;

R^8 and R^9 are independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocycle;

Cycle is a 3-8 membered fused cyclic group optionally substituted with 1, 2, 3, or 4 substituents; exemplary Cycle groups include carbocycle (e.g. cyclopropane, cyclohexane, or cyclohexene), heterocycle (e.g. oxetane, of piperazine), aryl (e.g. phenyl), or a heteroaryl group (e.g. pyridine, furan, or pyrrole) as appropriate and allowed by valence;

~~Linker^{E} is~~  ;


~~R^{30} is selected from Cl, Br, I, $-NR^6H$, $-OH$, $-N_3$, $-SH$,~~  ;

~~$-C(O)N(CH_3)OCH_3$, $-B(OR^6)(OR^7)$, heterocycle, $-NR^6COR^3$, $-OCOR^3$ and $-COR^3$;~~

~~R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, and R^{19} are independently at each occurrence selected from the group consisting of a bond, alkyl, C(O), C(O)O, OC(O), SO_2, S(O), C(S), $C(O)NR^6$, $NR^6C(O)$, O, S, NR^6, $C(R^{21}R^{21})$, $P(O)(OR^6)O$, $P(O)(OR^6)$, $P(O)(NR^6R^7)NR^6$, $P(O)(NR^6R^7)$, amino acid, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, heterocycle, heteroaryl, $[(CH_2)_2O]_n$, $[O(CH_2)_2]_n$, $[OCH(CH_3)C(O)]_n$, $[C(O)CH(CH_3)O]_n$, $[OCH_2C(O)]_n$, $[C(O)CH_2O]_n$, fatty acid, unsaturated acid, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^{21};~~

~~n is independently selected at each instance from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;~~

~~R^{21} is independently at each occurrence selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, F, Cl, Br, I, hydroxyl, alkoxy, azide, amino, cyano, $-NR^6R^7$, $-NR^8SO_2R^3$, $-NR^8S(O)R^3$, haloalkyl, heteroalkyl, aryl, heteroaryl, heterocyclyl, $-SR^3$, $-C(O)OR^3$, $-C(O)NR^6NR^7$, $-OR^3$,~~  ~~and heterocycle; and~~

~~the optional substituents are selected from alkyl, alkenyl, alkynyl, haloalkyl, $-OR^6$, F, Cl, Br, I, NR^6R^7, heteroalkyl, cyano, nitro, $C(O)R^3$,~~  ~~, as allowed by valence such that a stable compound results.~~


~~80. The compound of claim 79, wherein R^{21} is independently at each occurrence selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, F, Cl, Br, I, hydroxyl, alkoxy, azide, amino, cyano, NR^6R^7, $NR^8SO_2R^3$, $NR^8S(O)R^3$, haloalkyl, heteroalkyl, aryl, heteroaryl, and heterocycle.~~

~~81. The compound of claim 79, wherein R^{2A} is aryl optionally substituted with 1, 2, or 3 substituents.~~


~~82. The compound of claim 79, wherein R^{2A} is heterocycle optionally substituted with 1, 2, or 3 substituents.~~

~~83. The compound of claim 79, wherein R^{2A} is heteroaryl containing 1 or 2 heteroatoms independently selected from N, O, and S optionally substituted with 1, 2, or 3 substituents.~~


~~84. The compound of claim 79, wherein R^{2A} is selected from:~~




~~85. The compound of claim 79, wherein R^{2A} is selected from:~~




~~86. The compound of claim 79, wherein R^{2A} is selected from:~~




~~87. The compound of claim 79, wherein R^{2A} is selected from:~~




88. The compound of claim 79, wherein R^{2A} is selected from:









89. The compound of claim 79, wherein R^{2A} is selected from:



90. A compound selected from:














;


or a pharmaceutically acceptable salt thereof.


91. A compound selected from:










































or a pharmaceutically acceptable salt thereof.


92. A pharmaceutical composition comprising a compound of any one of claims 79-91, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.


93. A method of treating a disorder mediated by ASGPR comprising administering an effective amount of compound of any one of claims 79-91, or a pharmaceutical salt thereof, to a patient in need thereof.


94. An ASGPR-binding extracellular protein degrader compound of formula:






Linker^A
Linker^B
Extracellular Protein Targeting Ligand
HO
R^200
OH
X_1
R^1
R^5



Linker^A
O
O
HO
R^200
OH
Extracellular Protein Targeting Ligand
Linker^C
Linker^A
O
O
HO
R^200
OH
O
O
Linker^A
HO
R^200
OH
O
O
Linker^A
Linker^C
Extracellular Protein Targeting Ligand
HO
R^200
OH
X1
Linker^A
O
HO
R^200
OH
Extracellular Protein Targeting Ligand
Linker^C
Linker^A
X1
O
HO
R^200
OH



X1
O
Linker^A
HO
R^200
OH
X1
O
Linker^A
Linker^C
Extracellular Protein Targeting Ligand
HO
R^200
OH


Linker^A
O
R^1
HO
R^200
OH
Extracellular Protein Targeting Ligand
Linker^C
Linker^A
O
R^1
HO
R^200
OH


R^5
O
Linker^A
HO
R^200
OH
R^5
O
Linker^A
Linker^C
Extracellular Protein Targeting Ligand
HO
R^200
OH


Linker^A
HO
R^200
OH
Extracellular Protein Targeting Ligand
Linker^D
Linker^A
Linker^A
Linker^A
Linker^D
Extracellular Protein Targeting Ligand
Linker^A


X1
O
Linker^A
HO
R^200
OH
Extracellular Protein Targeting Ligand
Linker^D
Linker^A
X1
O
HO
R^200
OH
Linker^A
X1
O
HO
R^200
OH
X1
O
Linker^A
HO
R^200
OH
X1
O
Linker^A
Linker^D
Extracellular Protein Targeting Ligand
HO
R^200
OH
X1
O
Linker^A
HO
R^200
OH




~~or a pharmaceutically acceptable salt thereof~~

~~wherein:~~

~~X^1 is 1 to 5 groups independently selected from O, S, N(R^6), and C(R^4)(R^4), wherein if X^1 is 1 group then X^1 is O, S, N(R^6), or C(R^4)(R^4), if X^1 is 2 groups then no more than 1 group of X^1 is O, S, or N(R^6), if X^1 is 3, 4, or 5 groups then no more than 2 groups of X^1 are O, S, or N(R^6);~~

R^{200} is $NR^8C(O)R^3$, NR^6-alkyl, OR^8, heteroaryl, $NR^8S(O)_2R^3$, or NR^6-heteroalkyl, each of which R^{200} substituents is optionally substituted with 1, 2, 3, or 4 substituents;

when compounds are "optionally substituted" they may be substituted as allowed by valence by groups selected from alkyl, alkenyl, alkynyl, haloalkyl (including C_1-C_4haloalkyl), OR^6, F, Cl, Br, I, NR^6R^7, heteroalkyl, heterocycle, heteroaryl, aryl, cyano, nitro, hydroxyl, azide, amide, SR^3, $S(O)(NR^6)R^3$, $NR^8C(O)R^3$, $C(O)NR^6R^7$, $C(O)OR^3$, $C(O)R^3$, SF_5, , , , and , wherein the optional substituent is selected such that a stable compound results;

R^1 and R^5 are independently selected from hydrogen, heteroalkyl, C_0-C_6alkyl-cyano, alkyl, alkenyl, alkynyl, haloalkyl, F, Cl, Br, I, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocycloalkyl, haloalkoxy, -O-alkenyl, -O-alkynyl, C_0-C_6alkyl-OR^6, C_0-C_6alkyl-SR^6, C_0-C_6alkyl-NR^6R^7, C_0-C_6alkyl-$C(O)R^3$, C_0-C_6alkyl-$S(O)R^3$, C_0-C_6alkyl-$C(S)R^3$, C_0-C_6alkyl-$S(O)_2R^3$, C_0-C_6alkyl-$N(R^8)$-$C(O)R^3$, C_0-C_6alkyl-$N(R^8)$-$S(O)R^3$, C_0-C_6alkyl-$N(R^8)$-$C(S)R^3$, C_0-C_6alkyl-$N(R^8)$-$S(O)_2R^3$, C_0-C_6alkyl-O-$C(O)R^3$, C_0-C_6alkyl-O-$S(O)R^3$, C_0-C_6alkyl-O-$C(S)R^3$, $-N{=}S(O)(R^3)_2$, C_0-C_6alkylN_3, and C_0-C_6alkyl-O-$S(O)_2R^3$, each of which is optionally substituted with 1, 2, 3, or 4 substituents;

R^3 at each occurrence is independently selected from hydrogen, alkyl, heteroalkyl, haloalkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, $-OR^8$, and $-NR^8R^9$;

R^4 is independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, haloalkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, OR^6, NR^6R^7, $C(O)R^3$, $S(O)R^3$, $C(S)R^3$, and $S(O)_2R^3$;

R^6 and R^7 are independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, haloalkyl, heteroaryl, heterocycle, -alkyl-OR^8, -alkyl-NR^8R^9, $C(O)R^3$, $S(O)R^3$, $C(S)R^3$, and $S(O)_2R^3$;

R^8 and R^9 are independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocycle;

each $Linker^A$ is a bond or a moiety that covalently links the ASGPR ligand to $Linker^B$;


~~Linker^{B} is a bond or a moiety that covalently links Linker^{A} to an Extracellular Protein Targeting Ligand;~~

~~Linker^{C} is a chemical group that links each Linker^{A} to the Extracellular Protein Targeting Ligand; and~~


~~Linker^{D} is a chemical group that links each Linker^{A} to the Extracellular Protein Targeting Ligand.~~


~~95. The compound of claim 94, wherein:~~

~~R^{200} is $-NR^{8}-C(O)-R^{3}$; and~~


~~optional substituents are selected from alkyl, alkenyl, alkynyl, haloalkyl, $-OR^{6}$, F, Cl, Br, I, $-NR^{6}R^{7}$, heteroalkyl, cyano, nitro, $C(O)R^{3}$,~~  ~~, and~~  ~~, as allowed by valence such that a stable compound results.~~

~~96. The compound of claim 94 or 95, wherein the compound is selected from:~~






~~, and~~



~~or a pharmaceutically acceptable salt thereof.~~


~~97. The compound of claim 94 or 95, wherein the compound is selected from:~~




~~and~~

~~or a pharmaceutically acceptable salt thereof.~~

~~98. The compound of claim 94 or 95, wherein the compound is selected from:~~



~~and~~




~~or a pharmaceutically acceptable salt thereof~~

~~99. The compound of any one of claims 94 to 98, wherein the Extracellular Protein Targeting Ligand targets an immunoglobin.~~

~~100. The compound of any one of claims 94 to 98, wherein the Extracellular Protein Targeting Ligand targets IgA.~~

~~101. The compound of claim 100, wherein the Extracellular Protein Targeting Ligand is:~~



~~102. The compound of any one of claims 94 to 98, wherein the Extracellular Protein Targeting Ligand targets IgG.~~

~~103. The compound of any one of claims 94 to 98, wherein the Extracellular Protein Targeting Ligand targets IgE.~~

~~104. The compound of any one of claims 94 to 98, wherein the Extracellular Protein Targeting Ligand targets TNF-α.~~

~~105. The compound of any one of claims 94 to 98, wherein the Extracellular Protein Targeting Ligand targets IL-1b.~~

~~106. The compound of any one of claims 94 to 98, wherein the Extracellular Protein Targeting Ligand targets IL-2.~~

~~107. The compound of any one of claims 94 to 98, wherein the Extracellular Protein Targeting Ligand targets IL-6.~~


~~108. The compound of any one of claims 94 to 98, wherein the Extracellular Protein Targeting Ligand targets IFN γ.~~


~~109. The compound of any one of claims 94 to 98, wherein the Extracellular Protein Targeting Ligand targets VEGF.~~


~~110. The compound of any one of claims 94 to 98, wherein the Extracellular Protein Targeting Ligand targets TGF-b1.~~


~~111. The compound of any one of claims 94 to 98, wherein the Extracellular Protein Targeting Ligand targets PCSK-9.~~


~~112. A compound selected from:~~





























or a pharmaceutically acceptable salt thereof.

113. A pharmaceutical composition comprising a compound of any one of claims 94 to 112 and a pharmaceutically acceptable carrier.

114. A method of treating a disorder mediated by an extracellular protein comprising administering an effective amount of a compound of any one of claims 94 to 112 that includes an Extracellular Protein Targeting Ligand that binds to the Extracellular Protein, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

115. The method of claim 114, wherein the extracellular protein is IgA and the disorder is selected from IgA nephropathy (Berger's disease), celiac disease, Crohn's disease, Henoch-Sconiein purpura (HSP), liner IgA bullous dermatosis, IgA pemphigus, dermatitis herpetiformis, inflammatory bowel disease (IBD), Sjögren's syndrome, ankylosing spondylitis, alcoholic liver cirrhosis, acquired immunodeficiency syndrome, IgA multiple myeloma, α chain disease, IgA monoclonal gammopathy, monoclonal gammopathy of undetermined significance (MGUS), and linear IgA bullous dermatosis.

116. The method of claim 114, wherein the extracellular protein is IgG and the disorder is selected from type 1 autoimmune pancreatitis, interstitial nephritis, Riedel's thyroiditis, storiform fibrosis, Mikulicz's disease, Küttner's tumor, inflammatory pseudotumors, mediastinal fibrosis, retroperitoneal fibrosis (Ormond's disease), aortitis, periaortitis, proximal biliary strictures, idiopathic hypocomplementic tubulointerstitial nephritis, multifocal fibrosclerosis, pachymeningitis, pancreatic enlargement, tumefactive lesions, pericarditis, rheumatoid arthritis (RA), inflammatory bowel disease, multiple sclerosis, myasthenic gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, warm autoimmune hemolytic anemia, ankylosing spondylitis, primary Sjögren's syndrome, psoriatic arthritis, and systemic lupus erythematosus (SLE),

~~sclerosing cholangitis, and IgG monoclonal gammopathy, monoclonal gammopathy of undetermined significance (MGUS).~~

~~117. The method of claim 114, wherein the extracellular protein is IgE and the disorder is selected from atopic asthma, allergic rhinitis, atopic dermatitis, IgE-mediated food allergy, IgE-mediated animal allergies, allergic conjunctivitis, allergic urticaria, anaphylactic shock, nasal polyposis, keratoconjunctivitis, mastocytosis, and eosinophilic gastrointestinal disease, bullous pemphigoid, chemotherapy induced hypersensitivity reaction, seasonal allergic rhinitis, interstitial cystitis, eosinophilic esophagitis, angioedema, acute interstitial nephritis, atopic eczema, eosinophilic bronchitis, chronic obstructive pulmonary disease, gastroenteritis, hyper-IgE syndrome (Job's Syndrome), IgE monoclonal gammopathy, and monoclonal gammopathy of undetermined significance (MGUS).~~

~~118. The method of claim 114, wherein the disorder is dementia or Alzheimer's disease.~~

~~119. The method of claim 114, wherein the extracellular protein is TNF-α and the disorder is selected from rheumatoid arthritis, inflammatory bowel disease, graft-vs-host disease, ankylosing spondylitis, psoriasis, hidradenitis suppurativa, refractory asthma, systemic lupis erthyematosus, diabetes, and the induction of cachexia.~~


~~120. The method of claim 114, wherein the extracellular protein is IL-2 and the disorder is selected from host versus graft rejection in transplants and autoimmune disorders, including, but not limited to, multiple sclerosis, idiopathic arthritis, iritis, anterior uveitis, IL-2 induced hypotension, and psoriasis.~~

~~121. The method of claim 114, wherein the extracellular protein is IL-6 and the disorder is selected from Castleman's disease, metastatic castration-associated prostate cancer, renal cell carcinoma, large-cell lung carcinoma, ovarian cancer, rheumatoid arthritis, and asthma.~~


~~122. The method of claim 114, wherein the extracellular protein is IFN-γ and the disorder is selected from rheumatoid arthritis, multiple sclerosis (MS), corneal transplant rejection, and various autoimmune skin diseases such as psoriasis, alopecia areata, vitiligo, and acne vulgaris.~~

~~123. The method of claim 114, wherein the disorder is a cancer.~~


1. An ASGPR-binding extracellular protein degrader compound of formula:




(I),




(I-d),




(II),




(II-d),




(III),




(III-d),




(IV),




(IV-d),




(V),




(V-d),




(VI),




(VI-d),




(VII),




(VIII),




(I-Bi),




(I-d-Bi),




(II-Bi),




(II-d-Bi),




(III-Bi),




(III-d-Bi),




(IV-Bi),




(IV-d-Bi),




(V-Bi),




(V-d-Bi),




(VI-Bi),




(VI-d-Bi),




(VII-Bi),




(VIII-Bi),


Extracellular Protein Targeting Ligand
Linker^D
Linker^A
Linker^A
Linker^A
O
O
HO
R2
OH


(I-Tri),


Extracellular Protein Targeting Ligand
Linker^D
Linker^A
Linker^A
Linker^A
O
O
HO
R2
OH


(I-d-Tri),




(II-Tri),




(II-d-Tri),




(III-Tri),




(III-d-Tri),




(IV-Tri),




(IV-d-Tri),


Extracellular Protein Targeting Ligand
Linker^D
Linker^A
O
R^1
R^2
HO
OH


(V-Tri),


Extracellular Protein Targeting Ligand
Linker^D
Linker^A
O
R^1
R^2
HO
OH


(V-d-Tri),




(VI-Tri),



(VI-d-Tri),



(VII-Tri), or



(VIII-Tri),


or a pharmaceutically acceptable salt thereof

wherein:

X^1 is 1 to 5 groups independently selected from O, S, $N(R^6)$, and $C(R^4)(R^4)$, wherein if X^1 is 1 group then X^1 is O, S, $N(R^6)$, or $C(R^4)(R^4)$, if X^1 is 2 groups then no more than 1 group of X^1 is O, S, or $N(R^6)$, if X^1 is 3, 4, or 5 groups then no more than 2 groups of X^1 are O, S, or $N(R^6)$;

R^2 is selected from

(i) aryl, heterocycle, and heteroaryl containing 1 or 2 heteroatoms independently selected from N, O, and S, each of which aryl, heterocycle, and heteroaryl is optionally substituted with 1, 2, 3, or 4 substituents;

(ii) , and ;

(iii) $-NR^8-S(O)-R^3$, $-NR^8-C(S)-R^3$, $-NR^8-S(O)(NR^6)-R^3$, $-N=S(O)(R^3)_2$, $-NR^8C(O)NR^9S(O)_2R^3$, $-NR^8-S(O)_2-R^{10}$, and $-NR^8-C(NR^6)-R^3$ each of which is optionally substituted with 1, 2, 3, or 4 substituents; and

(iv) hydrogen, R^{10}, alkyl-$C(O)-R^3$, $-C(O)-R^3$, alkyl, haloalkyl, $-OC(O)R^3$, and $-NR^8-C(O)R^{10}$;

R^{10} is selected from aryl, alkyl-$NR^8-C(O)-R^3$, alkyl-aryl, alkyl-heteroaryl with 1, 2, or 4 heteroatoms, alkyl-cyano, alkyl-OR^6, alkyl-NR^6R^8, $NR^8-NR^6-C(O)R^3$, $NR^8-S(O)_2-R^3$, alkenyl, allyl, alkynyl, $-NR^6$-alkenyl, -O-alkenyl, $-NR^6$-alkynyl, $-NR^6$-heteroaryl, $-NR^6$-aryl, -O-heteroaryl, -O-aryl, and -O-alkynyl, each of which R^{10} is optionally substituted with 1, 2, 3, or 4 substituents;

R^1 and R^5 are independently selected from hydrogen, heteroalkyl, C_0-C_6alkyl-cyano, alkyl, alkenyl, alkynyl, haloalkyl, F, Cl, Br, I, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocycloalkyl, haloalkoxy, -O-alkenyl, -O-alkynyl, C_0-C_6alkyl-OR^6, C_0-C_6alkyl-SR^6, C_0-C_6alkyl-NR^6R^7, C_0-C_6alkyl-$C(O)R^3$, C_0-C_6alkyl-$S(O)R^3$, C_0-C_6alkyl-$C(S)R^3$, C_0-C_6alkyl-$S(O)_2R^3$, C_0-C_6alkyl-$N(R^8)$-$C(O)R^3$, C_0-C_6alkyl-$N(R^8)$-$S(O)R^3$, C_0-C_6alkyl-$N(R^8)$-$C(S)R^3$, C_0-C_6alkyl-$N(R^8)$-$S(O)_2R^3$ C_0-C_6alkyl-O-$C(O)R^3$, C_0-C_6alkyl-O-$S(O)R^3$, C_0-C_6alkyl-O-$C(S)R^3$, $-N=S(O)(R^3)_2$, C_0-C_6alkylN_3, and C_0-C_6alkyl-O-$S(O)_2R^3$, each of which is optionally substituted with 1, 2, 3, or 4 substituents;

R^3 at each occurrence is independently selected from hydrogen, alkyl, heteroalkyl, haloalkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, $-OR^8$, and $-NR^8R^9$;

R^4 is independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, haloalkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, $-OR^6$, $-NR^6R^7$, $C(O)R^3$, $S(O)R^3$, $C(S)R^3$, and $S(O)_2R^3$;

R^6 and R^7 are independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, haloalkyl, heteroaryl, heterocycle, -alkyl-OR^8, -alkyl-NR^8R^9, $C(O)R^3$, $S(O)R^3$, $C(S)R^3$, and $S(O)_2R^3$;

R^8 and R^9 are independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocycle;

Cycle is a 3-8 membered fused cyclic group optionally substituted with 1, 2, 3, or 4 substituents;


each $Linker^A$ is a bond or a moiety that covalently links the ASGPR ligand to $Linker^B$;

$Linker^B$ is a bond or a moiety that covalently links $Linker^A$ to an Extracellular Protein Targeting Ligand;

$Linker^C$ is a chemical group that links each $Linker^A$ to the Extracellular Protein Targeting Ligand; and

$Linker^D$ is a chemical group that links each $Linker^A$ to the Extracellular Protein Targeting Ligand; and

wherein, when R^2 is NR^6-alkenyl, -NR^6-alkynyl,-NR^8-$C(O)R^{10}$, -NR^8-$S(O)_2$-alkenyl, -NR^8-$S(O)_2$-alkynyl, -NR^6-heteroaryl, or -NR^6-aryl, then Extracellular Protein Targeting Ligand does not comprise an oligonucleotide; and

the optional substituents are selected from alkyl, alkenyl, alkynyl, haloalkyl, -OR^6, F, Cl, Br, I, -NR^6R^7, heteroalkyl, cyano, nitro, $C(O)R^3$, , as allowed by valence such that a stable compound results.

2. The compound of claim 1, wherein R^{10} is selected from alkenyl, allyl, alkynyl, -NR^6-alkenyl, -O-alkenyl, -NR^6-alkynyl, -O-alkynyl, -NR^6-heteroaryl, -NR^6-aryl, -O-heteroaryl, -O-aryl, and -O-alkynyl, each of which R^{10} is optionally substituted with 1, 2, 3, or 4 substituents.
3. The compound of claim 1, wherein R^2 is aryl optionally substituted with 1, 2, or 3 substituents.
4. The compound of claim 1, wherein R^2 is heterocycle optionally substituted with 1, 2, or 3 substituents.


5. The compound of claim 1, wherein R^2 is heteroaryl containing 1 or 2 heteroatoms independently selected from N, O, and S optionally substituted with 1, 2, or 3 substituents.

6. The compound of claim 1, wherein R^2 is -NR^6-heteroaryl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkyl, alkenyl, haloalkyl, -OR^6, F, Cl, Br, -NR^6R^7, heteroalkyl, cyano, nitro, and $C(O)R^3$.



7. The compound of claim 1, wherein R^2 is -NR^6-heteroaryl substituted with 1 or 2 substituents independently selected from the group consisting of alkyl, haloalkyl, -OR^6, F, Cl, and -NR^6R^7.

8. The compound of claim 7, wherein the 1 or 2 substituents are independently selected from the group consisting of haloalkyl, F, and Cl.


9. The compound of any one of claims 6-8, wherein the heteroaryl of -NR^6-heteroaryl is selected from:


, and .


10. The compound of claim 1, wherein R^2 is selected from:



and .


11. The compound of claim 1, wherein R^2 is selected from:


, and .


12. The compound of claim 1, wherein R^2 is selected from:




13. The compound of claim 1, wherein R^2 is selected from:




14. The compound of claim 1, wherein R^2 is selected from:




.





15. The compound of claim 1, wherein R^2 is selected from:




16. The compound of claim 1, wherein R^2 is selected from:




, and


.


17. The compound of claim 1, wherein R^2 is selected from:

,

, and .


18. The compound of claim 1, wherein R^2 is selected from:

,

, and .

19. The compound of claim 1, wherein R^2 is selected from alkenyl, alkynyl, -NR^6-alkenyl, -O-alkenyl, -NR^6-alkynyl, -O-alkynyl, alkyl-C(O)alkyl, alkyl, haloalkyl, -$OC(O)R^3$, and -NR^6-$C(O)R^{10}$.


20. The compound of any one of claims 1 to 19, wherein the compound is of Formula



;

or a pharmaceutically acceptable salt thereof.


21. The compound of any one of claims 1 to 19, wherein the compound is of Formula



;

or a pharmaceutically acceptable salt thereof.


22. The compound of any one of claims 1 to 19, wherein the compound is of Formula



;

or a pharmaceutically acceptable salt thereof.

23. The compound of any one of claims 1 to 19, wherein the compound is of Formula



;


or a pharmaceutically acceptable salt thereof.

24. The compound of claim 22 or 23, wherein X_1 is 2, 3, or 4 groups selected from O, S, $N(R^6)$, and $C(R^4)(R^4)$.

25. The compound of claim 22 or 23, wherein X_1 is -O-$C(R^4)(R^4)$-, -$C(R^4)(R^4)$-NR^6-, or -$C(R^4)(R^4)$-S-.

26. The compound of claim 25, wherein each R^4 is hydrogen.


27. The compound of any one of claims 1 to 19, wherein the compound is of Formula



;

or a pharmaceutically acceptable salt thereof.


28. The compound of any one of claims 1 to 19, wherein the compound is of Formula




;

or a pharmaceutically acceptable salt thereof.

29. The compound of any one of claims 1 to 19, wherein the compound is of Formula




or




;

or a pharmaceutically acceptable salt thereof.

30. The compound of claim 29, wherein Cycle is selected from:





,




, and .


31. The compound of claim 29, wherein Cycle is selected from:





32. The compound of claim 29, wherein Cycle is selected from:





33. The compound of any one of claims 1 to 32, wherein R^1 and R^5 are selected from hydrogen, alkyl, F, Cl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocycloalkyl, haloalkoxy, C_0-C_6alkyl-OR^6, C_0-C_6alkyl-SR^6, C_0-C_6alkyl-NR^6R^7, C_0-C_6alkyl-$C(O)R^3$, C_0-C_6alkyl-$S(O)R^3$, C_0-C_6alkyl-$C(S)R^3$, and C_0-C_6alkyl-$S(O)_2R^3$ each of which is optionally substituted with 1, 2, 3, or 4 substituents.

34. The compound of any one of claims 1 to 32, wherein R^1 and R^5 are selected from hydrogen, C_0-C_6alkyl-OR^6, C_0-C_6alkyl-SR^6, C_0-C_6alkyl-NR^6R^7, C_0-C_6alkyl-$C(O)R^3$, C_0-C_6alkyl-$S(O)R^3$, C_0-C_6alkyl-$C(S)R^3$, and C_0-C_6alkyl-$S(O)_2R^3$ each of which is optionally substituted with 1, 2, or 3 substituents.

35. The compound of any one of claims 1 to 32, wherein R^1 and R^5 are selected from hydrogen, C_0-C_6alkyl-OR^6, and C_0-C_6alkyl-NR^6R^7.

36. The compound of any one of claims 1 to 35, wherein R^3 is selected from aryl, heteroaryl, and heterocycle.

37. The compound of any one of claims 1 to 35, wherein R^3 is -OR^8.

38. The compound of any one of claims 1 to 35, wherein R^3 is -NR^8R^9.

39. The compound of any one of claims 1 to 38, wherein R^6 and R^7 are independently selected at each occurrence from hydrogen, alkyl, aryl, haloalkyl, heteroaryl, heterocycle, $C(O)R^3$, $S(O)R^3$, $C(S)R^3$, and $S(O)_2R^3$.

40. The compound of any one of claims 1 to 38, wherein R^6 and R^7 are independently selected at each occurrence from hydrogen, alkyl, and $C(O)R^3$, $S(O)R^3$, $C(S)R^3$, and $S(O)_2R^3$.


41. The compound of any one of claims 1 to 40, wherein at least one of R^6 and R^7 are hydrogen.

42. The compound of any one of claims 1 to 41, wherein R^8 and R^9 are independently selected at each occurrence from hydrogen, alkyl, aryl, heteroaryl, and heterocycle.


43. The compound of any one of claims 1 to 41, wherein R^8 and R^9 are independently selected at each occurrence from hydrogen and alkyl.


44. The compound of any one of claims 1 to 41, wherein R^8 and R^9 are both hydrogen at each occurrence.

45. The compound of any one of claims 1 to 44, wherein $Linker^A$ is selected from:



, , and .

46. The compound of any one of claims 1 to 44, wherein $Linker^A$ is selected from:



, , , and


.

47. The compound of any one of claims 1 to 44, wherein $Linker^A$ is selected from:


, , and .

48. The compound of any one of claims 1 to 47, wherein $Linker^B$ is:


;

wherein:

R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, and R^{20} are independently at each occurrence selected from the group consisting of a bond, alkyl, -C(O)-, -C(O)O-, -OC(O)-, -SO_2-, -S(O)-, -C(S)-, -C(O)NR^6-, -NR^6C(O)-, -O-, -S-, -NR^6-, -C($R^{21}R^{21}$)-, -P(O)(R^3)O-, -P(O)(R^3)-, a divalent residue of a natural or unnatural amino acid, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, heterocycle, heteroaryl, -CH_2CH_2-[O-$(CH_2)_2$]$_n$-O-, -CH_2CH_2-[O-$(CH_2)_2$]$_n$-NR^6-, -CH_2CH_2-[O-$(CH_2)_2$]$_n$-, -[-$(CH_2)_2$-O-]$_n$-, -[O-$(CH_2)_2$]$_n$-, -[O-CH(CH_3)C(O)]$_n$-, -[C(O)-CH(CH_3)-O]$_n$-, -[O-CH_2C(O)]$_n$-, -[C(O)-CH_2-O]$_n$-, a divalent residue of a fatty acid, a divalent residue of an unsaturated or saturated mono- or di-carboxylic acid, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^{21};

n is independently selected at each instance from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and


R^{21} is independently at each occurrence selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, F, Cl, Br, I, hydroxyl, alkoxy, azide, amino, cyano, -NR^6R^7, -$NR^8SO_2R^3$, -NR^8S(O)R^3, haloalkyl, heteroalkyl, aryl, heteroaryl, heterocyclyl, -SR^3, -C(O)OR^3, -C(O)NR^6NR^7, -OR^3,  and heterocycle.


49. The compound of claim 48, wherein R^{21} is independently at each occurrence selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, F, Cl, Br, I, hydroxyl, alkoxy, azide, amino, cyano, -NR^6R^7, -$NR^8SO_2R^3$, -NR^8S(O)R^3, haloalkyl, heteroalkyl, aryl, heteroaryl, and heterocycle.


50. The compound of claim 48 or 49, wherein 1, 2, 3, or 4 of R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, and R^{19} is bond.

51. The compound of claim 48 or 49, wherein 1, 2, 3, or 4 of R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, and R^{19} is an amino acid.

52. The compound of any one of claims 1 to 51, wherein $Linker^B$ is selected from:







, 

, and 


.


53. The compound of any one of claims 1 to 51, wherein $Linker^B$ is selected from:


, 
, 
, and



.

54. The compound of any one of claims 1 to 51, wherein $Linker^B$ is selected from the group consisting of:








and


; wherein tt is 1 and ss is 2.


55. The compound of any one of claims 1 to 47, wherein the compound is selected from:




(I-Bi),




(II-Bi),




(III-Bi),




(IV-Bi),




(V-Bi),



(VI-Bi),




(VII-Bi), and



(VIII-Bi);

or a pharmaceutically acceptable salt thereof.

56. The compound of claim 55, wherein Linker^C is selected from:



.

wherein:

R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, and R^{20} are independently at each occurrence selected from the group consisting of a bond, alkyl, -C(O)-, -C(O)O-, -OC(O)-, -SO_2-, -S(O)-, -C(S)-, -C(O)NR^6-, -NR^6C(O)-, -O-, -S-, -NR^6-, -C($R^{21}R^{21}$)-, -P(O)(R^3)O-, -P(O)(R^3)-, a divalent residue of a natural or unnatural amino acid, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, heterocycle, heteroaryl, -CH_2CH_2-[O-$(CH_2)_2$]$_n$-O-, -CH_2CH_2-[O-$(CH_2)_2$]$_n$-NR^6-, -CH_2CH_2-[O-$(CH_2)_2$]$_n$-, -[-$(CH_2)_2$-O-]$_n$-, -[O-$(CH_2)_2$]$_n$-, -[O-CH(CH_3)C(O)]$_n$-, -[C(O)-CH(CH_3)-O]$_n$-, -[O-CH_2C(O)]$_n$-, -[C(O)-CH_2-O]$_n$-, a divalent residue of a fatty acid, a divalent residue of an unsaturated or saturated mono- or di-carboxylic acid, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^{21};

n is independently selected at each instance from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;


R^{21} is independently at each occurrence selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, F, Cl, Br, I, hydroxyl, alkoxy, azide, amino, cyano, -NR^6R^7, -$NR^8SO_2R^3$,




-$NR^8S(O)R^3$, haloalkyl, heteroalkyl, aryl, heteroaryl, heterocyclyl, -SR^3, -$C(O)OR^3$, -$C(O)NR^6NR^7$, -OR^3,  and heterocycle; and




R^{22} is independently at each occurrence selected from the group consisting of alkyl, -C(O)N-, -NC(O)-, -N-, -$C(R^{21})$-, -P(O)O-, -P(O)-, -$P(O)(NR^6R^7)$N-, alkenyl, haloalkyl, aryl, heterocycle, and heteroaryl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^{21}.

57. The compound of claim 56, wherein R^{21} is independently at each occurrence selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, F, Cl, Br, I, hydroxyl, alkoxy, azide, amino, cyano, -NR^6R^7, -$NR^8SO_2R^3$, -$NR^8S(O)R^3$, haloalkyl, heteroalkyl, aryl, heteroaryl, and heterocycle.


58. The compound of claim 56 or 57, wherein $Linker^C$ is selected from:

, , ,


, , ,

, , and .


59. The compound of any one of claims 1 to 47, wherein the compound is selected from:


Extracellular Protein Targeting Ligand
Linker^D
Linker^A
Linker^A
Linker^A
O
HO
R^2
OH


(I-Tri),


Linker^A
Linker^A
Linker^A
Linker^D
Extracellular Protein Targeting Ligand
O
HO
R^2
OH


(II-Tri),




(III-Tri),




(IV-Tri),


Linker^A
O
R^1
HO
R^2
OH
Extracellular Protein Targeting Ligand
Linker^D
Linker^A
O
R^1
HO
R^2
OH
Linker^A
O
R^1
HO
R^2
OH


(V-Tri),


R^5
O
Linker^A
HO
R^2
OH
R^5
O
Linker^A
Linker^D
Extracellular Protein Targeting Ligand
HO
R^2
OH
R^5
O
Linker^A
HO
R^2
OH

(VI-Tri),




(VII-Tri), and



(VIII-Tri);

or a pharmaceutically acceptable salt thereof.

60. The compound of claim 59, wherein Linker^D is selected from:



;

wherein:


R^{32} is independently at each occurrence selected from the group consisting of alkyl, N^+X^-, -C-, alkenyl, haloalkyl, aryl, heterocycle, and heteroaryl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^{21}; and

X^- is an anionic group.

61. The compound of any one of claims 1 to 60, wherein the Extracellular Protein Targeting Ligand targets an immunoglobin.

62. The compound of any one of claims 1 to 61, wherein the Extracellular Protein Targeting Ligand targets IgA.

63. The compound of claim 62, wherein the Extracellular Protein Targeting Ligand is:



.

64. The compound of any one of claims 1 to 61, wherein the Extracellular Protein Targeting Ligand targets IgG.

65. The compound of any one of claims 1 to 61, wherein the Extracellular Protein Targeting Ligand targets IgE.

66. The compound of any one of claims 1 to 60, wherein the Extracellular Protein Targeting Ligand targets TNF-α.

67. The compound of any one of claims 1 to 60, wherein the Extracellular Protein Targeting Ligand targets IL-1b.

68. The compound of any one of claims 1 to 60, wherein the Extracellular Protein Targeting Ligand targets IL-2.

69. The compound of any one of claims 1 to 60, wherein the Extracellular Protein Targeting Ligand targets IL-6.

70. The compound of any one of claims 1 to 60, wherein the Extracellular Protein Targeting Ligand targets IFN-γ.

71. The compound of any one of claims 1 to 60, wherein the Extracellular Protein Targeting Ligand targets VEGF.

72. The compound of any one of claims 1 to 60, wherein the Extracellular Protein Targeting Ligand targets TGF-b1.

73. The compound of any one of claims 1 to 60, wherein the Extracellular Protein Targeting Ligand targets PCSK-9.

74. A pharmaceutical composition comprising a compound of any one of claims 1 to 73 and a pharmaceutically acceptable carrier.

75. Use of a compound of any one of claims 1 to 73 that includes an Extracellular Protein Targeting Ligand that binds to Extracellular Protein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a disorder mediated by an effective amount of the Extracellular Protein in a patient.

76. The use of claim 75, wherein the extracellular protein is IgA and the disorder is selected from IgA nephropathy (Berger's disease), celiac disease, Crohn's disease, Henoch-Sconiein purpura (HSP), liner IgA bullous dermatosis, IgA pemphigus, dermatitis herpetiformis, inflammatory bowel disease (IBD), Sjögren's syndrome, ankylosing spondylitis, alcoholic liver cirrhosis, acquired immunodeficiency syndrome, IgA multiple myeloma, α-chain disease, IgA monoclonal gammopathy, monoclonal gammopathy of undetermined significance (MGUS), and linear IgA bullous dermatosis.

77. The use of claim 75, wherein the extracellular protein is IgG and the disorder is selected from type 1 autoimmune pancreatitis, interstitial nephritis, Riedel's thyroiditis, storiform fibrosis, Mikulicz's disease, Küttner's tumor, inflammatory pseudotumors, mediastinal fibrosis, retroperitoneal fibrosis (Ormond's disease), aortitis, periaortitis, proximal biliary strictures, idiopathic hypocomplementic tubulointerstitial nephritis, multifocal fibrosclerosis, pachymeningitis, pancreatic enlargement, tumefactive lesions, pericarditis, rheumatoid arthritis (RA), inflammatory bowel disease, multiple sclerosis, myasthenic gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, warm autoimmune hemolytic anemia, ankylosing spondylitis, primary Sjögren's syndrome, psoriatic arthritis, and systemic lupus erythematosus (SLE), sclerosing cholangitis, and IgG monoclonal gammopathy, monoclonal gammopathy of undetermined significance (MGUS).

78. The use of claim 75, wherein the extracellular protein is IgE and the disorder is selected from atopic asthma, allergic rhinitis, atopic dermatitis, IgE-mediated food allergy, IgE-

mediated animal allergies, allergic conjunctivitis, allergic urticaria, anaphylactic shock, nasal polyposis, keratoconjunctivitis, mastocytosis, and eosinophilic gastrointestinal disease, bullous pemphigoid, chemotherapy induced hypersensitivity reaction, seasonal allergic rhinitis, interstitial cystitis, eosinophilic esophagitis, angioedema, acute interstitial nephritis, atopic eczema, eosinophilic bronchitis, chronic obstructive pulmonary disease, gastroenteritis, hyper-IgE syndrome (Job's Syndrome), IgE monoclonal gammopathy, and monoclonal gammopathy of undetermined significance (MGUS).

79. The use of claim 75, wherein the disorder is dementia or Alzheimer's disease.

80. The use of claim 75, wherein the extracellular protein is TNF-α and the disorder is selected from rheumatoid arthritis, inflammatory bowel disease, graft-vs-host disease, ankylosing spondylitis, psoriasis, hidradenitis suppurativa, refractory asthma, systemic lupis erthyematosus, diabetes, and the induction of cachexia.


81. The use of claim 75, wherein the extracellular protein is IL-2 and the disorder is selected from host versus graft rejection in transplants and autoimmune disorders, including, but not limited to, multiple sclerosis, idiopathic arthritis, iritis, anterior uveitis, IL-2 induced hypotension, and psoriasis.

82. The use of claim 75, wherein the extracellular protein is IL-6 and the disorder is selected from Castleman's disease, metastatic castration-associated prostate cancer, renal cell carcinoma, large-cell lung carcinoma, ovarian cancer, rheumatoid arthritis, and asthma.


83. The use of claim 75, wherein the extracellular protein is IFN-γ and the disorder is selected from rheumatoid arthritis, multiple sclerosis (MS), corneal transplant rejection, and various autoimmune skin diseases such as psoriasis, alopecia areata, vitiligo, and acne vulgaris.

84. The use of claim 75, wherein the disorder is a cancer.


85. A compound of formula:




(IX),





(X),





(XI),



(XII),


(XIII),


(XIV),


(XV), or


(XVI),

or a salt thereof;

wherein:

R^L is selected from R^5 and $Linker^E$;

R^{L2} is selected from R^6 and $Linker^E$;

X^1 is 1 to 5 contiguous atoms independently selected from O, S, $N(R^6)$, and $C(R^4)(R^4)$, wherein if X^1 is 1 atom then X^1 is O, S, $N(R^6)$, or $C(R^4)(R^4)$, if X^1 is 2 atoms then no more than 1 atom of X^1 is O, S, or $N(R^6)$, if X^1 is 3, 4, or 5 atoms then no more than 2 atoms of X^1 are O, S, or $N(R^6)$;

R^{2A} is selected from

(i) aryl, alkyl-NR^8-C(O)-R^3, alkyl-aryl, alkyl-heteroaryl with 1, 2, or 4 heteroatoms, alkyl-cyano, alkyl-OR^6, alkyl-NR^6R^8, NR^8-NR^6-C(O)R^3, NR^8-$S(O)_2$-R^3, alkenyl, allyl, alkynyl, -NR^6-alkenyl, -O-alkenyl, -NR^6-alkynyl, -NR^6-heteroaryl, -NR^6-aryl, -O-heteroaryl, -O-aryl, and -O-alkynyl, each of which R^{10} is optionally substituted with 1, 2, 3, or 4 substituents;

R^1 and R^5 are independently selected from hydrogen, heteroalkyl, C_0-C_6alkyl-cyano, alkyl, alkenyl, alkynyl, haloalkyl, F, Cl, Br, I, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocycloalkyl, haloalkoxy, -O-alkenyl, -O-alkynyl, C_0-C_6alkyl-OR^6, C_0-C_6alkyl-SR^6, C_0-C_6alkyl-NR^6R^7, C_0-C_6alkyl-C(O)R^3, C_0-C_6alkyl-S(O)R^3, C_0-C_6alkyl-C(S)R^3, C_0-C_6alkyl-$S(O)_2R^3$, C_0-C_6alkyl-$N(R^8)$-C(O)R^3, C_0-C_6alkyl-$N(R^8)$-S(O)R^3, C_0-C_6alkyl-$N(R^8)$-C(S)R^3, C_0-C_6alkyl-$N(R^8)$-$S(O)_2R^3$ C_0-C_6alkyl-O-C(O)R^3, C_0-C_6alkyl-O-S(O)R^3, C_0-

C_6alkyl-O-C(S)R^3, -N=S(O)(R^3)$_2$, C_0-C_6alkylN$_3$, and C_0-C_6alkyl-O-S(O)$_2R^3$, each of which is optionally substituted with 1, 2, 3, or 4 substituents;


R^3 at each occurrence is independently selected from hydrogen, alkyl, heteroalkyl, haloalkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, -OR^8, or -NR^8R^9;


R^4 is independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, haloalkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, -OR^6, -NR^6R^7, C(O)R^3, S(O)R^3, C(S)R^3, and S(O)$_2R^3$;

R^6 and R^7 are independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, haloalkyl, heteroaryl, heterocycle, -alkyl-OR^8, -alkyl-NR^8R^9, C(O)R^3, S(O)R^3, C(S)R^3, and S(O)$_2R^3$;

R^8 and R^9 are independently selected at each occurrence from hydrogen, heteroalkyl, alkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocycle;

Cycle is a 3-8 membered fused cyclic group optionally substituted with 1, 2, 3, or 4 substituents;;

Linker^E is ;



R^{30} is selected from Cl, Br, I, -NR^6H, -OH, -N$_3$, -SH, , , -C(O)N(CH_3)OCH_3, -B(OR^6)(OR^7), heterocycle, -NR^6COR^3, -OCOR^3 and -COR^3,

R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, and R^{19} are independently at each occurrence selected from the group consisting of a bond, alkyl, -C(O)-, -C(O)O-, -OC(O)-, -SO$_2$-, -S(O)-, -C(S)-, -C(O)NR^6-, -NR^6C(O)-, -O-, -S-, -NR^6-, -C($R^{21}R^{21}$)-, -P(O)(OR^6)O-, -P(O)(OR^6)-, -P(O)(NR^6R^7)NR^6-, -P(O)(NR^6R^7)-, amino acid, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, heterocycle, heteroaryl, -[-(CH_2)$_2$-O-]$_n$-, -[O-(CH_2)$_2$]$_n$-, -[O-CH(CH_3)C(O)]$_n$-, -[C(O)-CH(CH_3)-O]$_n$-, -[O-CH_2C(O)]$_n$-, -[C(O)-CH_2-O]$_n$-, fatty acid, unsaturated acid, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^{21};

n is independently selected at each instance from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

R^{21} is independently at each occurrence selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, F, Cl, Br, I, hydroxyl, alkoxy, azide, amino, cyano, -NR^6R^7, -$NR^8SO_2R^3$,

-$NR^8S(O)R^3$, haloalkyl, heteroalkyl, aryl, heteroaryl, heterocyclyl, -SR^3, -$C(O)OR^3$, -$C(O)NR^6NR^7$, -OR^3,  and heterocycle; and

the optional substituents are selected from alkyl, alkenyl, alkynyl, haloalkyl, -OR^6, F, Cl, Br, I, -NR^6R^7, heteroalkyl, cyano, nitro, $C(O)R^3$, , , , and , as allowed by valence such that a stable compound results.

86. The compound of claim 85, wherein R^{21} is independently at each occurrence selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, F, Cl, Br, I, hydroxyl, alkoxy, azide, amino, cyano, -NR^6R^7, -$NR^8SO_2R^3$, -$NR^8S(O)R^3$, haloalkyl, heteroalkyl, aryl, heteroaryl, and heterocycle.


87. The compound of claim 85, wherein R^{2A} is aryl optionally substituted with 1, 2, or 3 substituents.

88. The compound of claim 85, wherein R^{2A} is -NR^6-heteroaryl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkyl, alkenyl, haloalkyl, -OR^6, F, Cl, Br, -NR^6R^7, heteroalkyl, cyano, nitro, and $C(O)R^3$.


89. The compound of claim 85, wherein R^{2A} is -NR^6-heteroaryl substituted with 1 or 2 substituents independently selected from the group consisting of alkyl, haloalkyl, -OR^6, F, Cl, and -NR^6R^7.


90. The compound of claim 89, wherein the 1 or 2 substituents are independently selected from the group consisting of haloalkyl, F, and Cl.

91. The compound of any one of claims 85-90, wherein the heteroaryl of -NR^6-heteroaryl is selected from:




92. The compound of claim 85, wherein R^{2A} is selected from:








and .


93. A compound selected from:



















































































;


or a pharmaceutically acceptable salt thereof.


94. A compound selected from:







































































































































































































or a pharmaceutically acceptable salt thereof.